FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3036103667> ?p ?o ?g. }

• W3036103667 endingPage "1188" @default.
• W3036103667 startingPage "1179" @default.
• W3036103667 abstract "PurposeWe performed a secondary analysis of a phase 3 randomized trial to determine the influence of sequencing of radiation therapy and androgen deprivation therapy (ADT) on posttreatment testosterone recovery and implications of testosterone recovery on subsequent relapse.Methods and MaterialsPatients with localized prostate cancer with Gleason score ≤7, clinical stage T1b to T3a, and prostate-specific antigen <30 ng/mL were randomized to neoadjuvant and concurrent ADT for 6 months starting 4 months before prostate radiation therapy (NHT arm) or concurrent and adjuvant ADT for 6 months starting simultaneously with radiation therapy (CAHT arm). Full testosterone recovery (FTR) was defined as recovery of testosterone to >10.5 nmol/L in patients with baseline ≥10.5 nmol/L or to baseline level in patients with baseline <10.5 nmol/L. Restricted mean survival time (RMST) since ADT initiation to supracastrate testosterone level (>1.7 nmol/L), and to FTR was compared between the arms using a truncation time point of 36 months.ResultsThe adjusted difference in RMST to supracastrate testosterone between the CAHT and NHT arm was 1.5 months (95% confidence interval [CI], 0.5-2.5; P = .005). No difference was noted in RMST to FTR between the arms (18.7 vs 18.5 months, adjusted difference: 0.5; 95% CI, –1.4 to 2.4; P = .61). There was no evidence of heterogeneity of treatment effect (interaction P = .76) on risk of relapse over subgroups stratified by testosterone recovery to supracastrate level at 15 months after start of ADT. Based on a multistate Markov model, no independent effect of time to FTR on risk of subsequent relapse was observed (adjusted hazard ratio: 1.02; 95% CI, 0.96-1.08).ConclusionsPatients should be counseled that an additional 12 months on average is needed for FTR to occur after treatment with prostate radiation therapy and 6 months of ADT. This is independent of the sequencing of ADT and radiation therapy. Furthermore, recovery of testosterone does not appear to affect the risk of subsequent relapse. We performed a secondary analysis of a phase 3 randomized trial to determine the influence of sequencing of radiation therapy and androgen deprivation therapy (ADT) on posttreatment testosterone recovery and implications of testosterone recovery on subsequent relapse. Patients with localized prostate cancer with Gleason score ≤7, clinical stage T1b to T3a, and prostate-specific antigen <30 ng/mL were randomized to neoadjuvant and concurrent ADT for 6 months starting 4 months before prostate radiation therapy (NHT arm) or concurrent and adjuvant ADT for 6 months starting simultaneously with radiation therapy (CAHT arm). Full testosterone recovery (FTR) was defined as recovery of testosterone to >10.5 nmol/L in patients with baseline ≥10.5 nmol/L or to baseline level in patients with baseline <10.5 nmol/L. Restricted mean survival time (RMST) since ADT initiation to supracastrate testosterone level (>1.7 nmol/L), and to FTR was compared between the arms using a truncation time point of 36 months. The adjusted difference in RMST to supracastrate testosterone between the CAHT and NHT arm was 1.5 months (95% confidence interval [CI], 0.5-2.5; P = .005). No difference was noted in RMST to FTR between the arms (18.7 vs 18.5 months, adjusted difference: 0.5; 95% CI, –1.4 to 2.4; P = .61). There was no evidence of heterogeneity of treatment effect (interaction P = .76) on risk of relapse over subgroups stratified by testosterone recovery to supracastrate level at 15 months after start of ADT. Based on a multistate Markov model, no independent effect of time to FTR on risk of subsequent relapse was observed (adjusted hazard ratio: 1.02; 95% CI, 0.96-1.08). Patients should be counseled that an additional 12 months on average is needed for FTR to occur after treatment with prostate radiation therapy and 6 months of ADT. This is independent of the sequencing of ADT and radiation therapy. Furthermore, recovery of testosterone does not appear to affect the risk of subsequent relapse." @default.
• W3036103667 created "2020-06-25" @default.
• W3036103667 creator A5008332143 @default.
• W3036103667 creator A5025965023 @default.
• W3036103667 creator A5027101830 @default.
• W3036103667 creator A5043559301 @default.
• W3036103667 creator A5066769964 @default.
• W3036103667 creator A5070757819 @default.
• W3036103667 creator A5076238068 @default.
• W3036103667 creator A5082004047 @default.
• W3036103667 date "2020-12-01" @default.
• W3036103667 modified "2023-10-14" @default.
• W3036103667 title "Impact of Sequencing of Androgen Suppression and Radiation Therapy on Testosterone Recovery in Localized Prostate Cancer" @default.
• W3036103667 cites W1545430154 @default.
• W3036103667 cites W1870480275 @default.
• W3036103667 cites W1907371083 @default.
• W3036103667 cites W1963897008 @default.
• W3036103667 cites W1975378455 @default.
• W3036103667 cites W1983850632 @default.
• W3036103667 cites W1991528069 @default.
• W3036103667 cites W2011284201 @default.
• W3036103667 cites W2025918036 @default.
• W3036103667 cites W2031748687 @default.
• W3036103667 cites W2035259770 @default.
• W3036103667 cites W2039377589 @default.
• W3036103667 cites W2040818579 @default.
• W3036103667 cites W2066131828 @default.
• W3036103667 cites W2066937933 @default.
• W3036103667 cites W2067736786 @default.
• W3036103667 cites W2069830079 @default.
• W3036103667 cites W2074956774 @default.
• W3036103667 cites W2088229392 @default.
• W3036103667 cites W2093867637 @default.
• W3036103667 cites W2106285196 @default.
• W3036103667 cites W2108864389 @default.
• W3036103667 cites W2125785593 @default.
• W3036103667 cites W2159273458 @default.
• W3036103667 cites W2296809578 @default.
• W3036103667 cites W2337386322 @default.
• W3036103667 cites W2465092116 @default.
• W3036103667 cites W2469323349 @default.
• W3036103667 cites W2536173378 @default.
• W3036103667 cites W2577699706 @default.
• W3036103667 cites W2592189527 @default.
• W3036103667 cites W2593907460 @default.
• W3036103667 cites W2603384438 @default.
• W3036103667 cites W2734786464 @default.
• W3036103667 cites W2742580607 @default.
• W3036103667 cites W2781996477 @default.
• W3036103667 cites W2811472135 @default.
• W3036103667 cites W2896978422 @default.
• W3036103667 cites W2900003817 @default.
• W3036103667 cites W2944110124 @default.
• W3036103667 cites W2945522282 @default.
• W3036103667 cites W2952903287 @default.
• W3036103667 cites W2989782958 @default.
• W3036103667 cites W2996677572 @default.
• W3036103667 doi "https://doi.org/10.1016/j.ijrobp.2020.06.017" @default.
• W3036103667 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32565318" @default.
• W3036103667 hasPublicationYear "2020" @default.
• W3036103667 type Work @default.
• W3036103667 sameAs 3036103667 @default.
• W3036103667 citedByCount "8" @default.
• W3036103667 countsByYear W30361036672021 @default.
• W3036103667 countsByYear W30361036672022 @default.
• W3036103667 countsByYear W30361036672023 @default.
• W3036103667 crossrefType "journal-article" @default.
• W3036103667 hasAuthorship W3036103667A5008332143 @default.
• W3036103667 hasAuthorship W3036103667A5025965023 @default.
• W3036103667 hasAuthorship W3036103667A5027101830 @default.
• W3036103667 hasAuthorship W3036103667A5043559301 @default.
• W3036103667 hasAuthorship W3036103667A5066769964 @default.
• W3036103667 hasAuthorship W3036103667A5070757819 @default.
• W3036103667 hasAuthorship W3036103667A5076238068 @default.
• W3036103667 hasAuthorship W3036103667A5082004047 @default.
• W3036103667 hasBestOaLocation W30361036671 @default.
• W3036103667 hasConcept C121608353 @default.
• W3036103667 hasConcept C126322002 @default.
• W3036103667 hasConcept C126894567 @default.
• W3036103667 hasConcept C143998085 @default.
• W3036103667 hasConcept C168563851 @default.
• W3036103667 hasConcept C203092338 @default.
• W3036103667 hasConcept C2776235491 @default.
• W3036103667 hasConcept C2777899217 @default.
• W3036103667 hasConcept C2777911890 @default.
• W3036103667 hasConcept C2779279991 @default.
• W3036103667 hasConcept C2780192828 @default.
• W3036103667 hasConcept C2781406297 @default.
• W3036103667 hasConcept C44249647 @default.
• W3036103667 hasConcept C509974204 @default.
• W3036103667 hasConcept C71315377 @default.
• W3036103667 hasConcept C71924100 @default.
• W3036103667 hasConceptScore W3036103667C121608353 @default.
• W3036103667 hasConceptScore W3036103667C126322002 @default.
• W3036103667 hasConceptScore W3036103667C126894567 @default.
• W3036103667 hasConceptScore W3036103667C143998085 @default.
• W3036103667 hasConceptScore W3036103667C168563851 @default.
• W3036103667 hasConceptScore W3036103667C203092338 @default.

• next